NexMed, Inc., a developer of transdermal products based on its proprietary NexACT drug delivery technology, has filed a new drug application for its topically applied alprostadil cream for the treatment of erectile dysfunction.
NexMed, Inc., a developer of transdermal products based on its proprietary NexACT drug delivery technology, has filed a new drug application for its topically applied alprostadil cream for the treatment of erectile dysfunction.
The company said it is also working with various pharmaceutical companies to explore the incorporation of NexACT into their existing drugs as a means of developing new patient-friendly transdermal products.
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.